Liver fat: A relevant target for dietary intervention? Summary of a unilever workshop

Journal of Nutritional Science

Volumn 6, Issue , 2017, Pages

  Peters, Harry P F ^a   Schrauwen, Patrick ^b   Verhoef, Petra ^a   Byrne, Christopher D ^c   Mela, David J ^a   Pfeiffer, Andreas F H ^d,e   Risérus, Ulf ^f   Rosendaal, Frits R ^g   Schrauwen Hinderling, Vera ^b  

^a UNILEVER RESEARCH VLAARDINGEN   (Netherlands)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^c and University of Bristol   (United Kingdom)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^e GERMAN INSTITUTE OF HUMAN NUTRITION   (Germany)

^f UPPSALA UNIVERSITY   (Sweden)

^g LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Cardiovascular disease; Diet; Liver fat; Type 2 diabetes

Indexed keywords

ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DIETITIAN; DISEASE ASSESSMENT; DISEASE COURSE; FAT INTAKE; FOOD INDUSTRY; HUMAN; IN VIVO STUDY; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID STORAGE; LIPOGENESIS; LIVER CIRRHOSIS; LIVER WEIGHT; METABOLIC DISORDER; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OBESITY; OUTCOME ASSESSMENT; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RISK FACTOR; RISK REDUCTION;

EID: 85018442980     PISSN: 20486790     EISSN: None     Source Type: Journal    
DOI: 10.1017/jns.2017.13     Document Type: Article

References (120)

1. Chalasani N, Younossi Z, Lavine JE, et al. (2012) The diagnosis and management of non-Alcoholic fatty liver disease: practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 55, 2005-2023.
2. Lim S, Oh TJ & Koh KK (2015) Mechanistic link between nonalcoholic fatty liver disease and cardiometabolic disorders. Int J Cardiol 201, 408-414.
3. Musso G, Gambino R, Cassader M, et al. (2011) Meta-Analysis: natural history of non-Alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann Med 43, 617-649.
4. Targher G & Byrne CD (2013) Nonalcoholic fatty liver disease: A novel cardiometabolic risk factor for type 2 diabetes and its complications. J Clin Endocrinol Metab 98, 483-495.
5. Targher G, Day CP & Bonora E (2010) Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. New Engl J Med 363, 1341-1350.
6. Than NN & Newsome PN (2015) A concise review of nonalcoholic fatty liver disease. Atherosclerosis 239, 192-202.
7. Loomba R & Sanyal AJ (2013) The global NAFLD epidemic. Nat Rev Gastroenterol Hepatol 10, 686-690.
8. Jacob S, Machann J, Rett K, et al. (1999) Association of increased intramyocellular lipid content with insulin resistance in lean nondiabetic offspring of type 2 diabetic subjects. Diabetes 48, 1113-1119.
9. Lindeboom L, Nabuurs CI, Hesselink MKC, et al. (2015) Proton magnetic resonance spectroscopy reveals increased hepatic lipid content after a single high-fat meal with no additional modulation by added protein. Am J Clin Nutr 101, 65-71.
10. Stephenson MC, Leverton E, Khoo EYH, et al. (2013) Variability in fasting lipid and glycogen contents in hepatic and skeletal muscle tissue in subjects with and without type 2 diabetes: A 1H and 13C MRS study. NMR Biomed 26, 1518-1526.
11. Szczepaniak LS, Nurenberg P, Leonard D, et al. (2005) Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population. Am J Physiol Endocrinol Metab 288, E462-E468.
12. Bjermo H, Iggman D, Kullberg J, et al. (2012) Effects of n-6 PUFAs compared with SFAs on liver fat, lipoproteins, and inflammation in abdominal obesity: A randomized controlled trial. Am J Clin Nutr 95, 1003-1012.
13. Bozzetto L, Prinster A, Annuzzi G, et al. (2012) Liver fat is reduced by an isoenergetic MUFA diet in a controlled randomized study in type 2 diabetic patients. Diabetes Care 35, 1429-1435.
14. Haufe S, Engeli S, Kast P, et al. (2011) Randomized comparison of reduced fat and reduced carbohydrate hypocaloric diets on intrahepatic fat in overweight and obese human subjects. Hepatology 53, 1504-1514.
15. Rosqvist F, Iggman D, Kullberg J, et al. (2014) Overfeeding polyunsaturated and saturated fat causes distinct effects on liver and visceral fat accumulation in humans. Diabetes 63, 2356-2368.
16. Zelber-Sagi S, Ratziu V & Oren R (2011) Nutrition and physical activity in NAFLD: An overview of the epidemiological evidence. World J Gastroenterol 17, 3377-3389.
17. Szczepaniak LS, Dobbins RL, Metzger GJ, et al. (2003) Myocardial triglycerides and systolic function in humans: in vivo evaluation by localized proton spectroscopy and cardiac imaging. Magn Reson Med 49, 417-423.
18. Thamer C, Machann J, Haap M, et al. (2004) Intrahepatic lipids are predicted by visceral adipose tissue mass in healthy subjects. Diabetes Care 27, 2726-2729.
19. Hoeks J, Hesselink MKC, Russell AP, et al. (2006) Peroxisome proliferator-Activated receptor-γ coactivator-1 and insulin resistance: Acute effect of fatty acids. Diabetologia 49, 2419-2426.
20. Bilet L, Van De Weijer T, Hesselink MKC, et al. (2011) Exercise-induced modulation of cardiac lipid content in healthy lean young men. Basic Res Cardiol 106, 307-315.
21. Bilet L, Brouwers B, Van Ewijk PA, et al. (2015) Acute exercise does not decrease liver fat in men with overweight or NAFLD. Sci Rep 5, 9709.
22. Schrauwen-Hinderling VB, Hesselink MKC, Meex R, et al. (2010) Improved ejection fraction after exercise training in obesity is accompanied by reduced cardiac lipid content. J Clin Endocrinol Metab 95, 1932-1938.
23. Keating SE, Hackett DA, Parker HM, et al. (2015) Effect of aerobic exercise training dose on liver fat and visceral adiposity. J Hepatol 63, 174-182.
24. Thoma C, Day CP & Trenell MI (2012) Lifestyle interventions for the treatment of non-Alcoholic fatty liver disease in adults: A systematic review. J Hepatol 56, 255-266.
25. Timmers S, Konings E, Bilet L, et al. (2011) Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans. Cell Metab 14, 612-622.
26. Schrauwen-Hinderling VB, Schrauwen P, Hesselink MKC, et al. (2003) The increase in intramyocellular lipid content is a very early response to training. J Clin Endocrinol Metab 88, 1610-1616.
27. Goodpaster BH, He J, Watkins S, et al. (2001) Skeletal muscle lipid content and insulin resistance: Evidence for a paradox in endurancetrained athletes. J Clin Endocrinol Metabol 86, 5755-5761.
28. Trevino MB, Mazur-Hart D, Machida Y, et al. (2015) Liver perilipin 5 expression worsens hepatosteatosis but not insulin resistance in high fat-fed mice. Mol Endocrinol 29, 1414-1425.
29. Krahmer N, Guo Y, Farese J, et al. (2009) SnapShot: lipid droplets. Cell 139, 1024.
30. Ekstedt M, Franzén LE, Mathiesen UL, et al. (2006) Long-Term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 44, 865-873.
31. Vernon G, Baranova A & Younossi ZM (2011) Systematic review: The epidemiology and natural history of non-Alcoholic fatty liver disease and non-Alcoholic steatohepatitis in adults. Alim Pharmacol Ther 34, 274-285.
32. Beymer C, Kowdley KV, Larson A, et al. (2003) Prevalence and predictors of asymptomatic liver disease in patients undergoing gastric bypass surgery. Arch Surg 138, 1240-1244.
33. Colicchio P, Tarantino G, Del GF, et al. (2005) Non-Alcoholic fatty liver disease in young adult severely obese non-diabetic patients in South Italy. Ann Nutr Metab 49, 289-295.
34. Kagansky N, Levy S, Keter D, et al. (2004) Non-Alcoholic fatty liver disease -A common and benign finding in octogenarian patients. Liver Int 24, 588-594.
35. Leite NC, Salles GF, Araujo ALE, et al. (2009) Prevalence and associated factors of non-Alcoholic fatty liver disease in patients with type-2 diabetes mellitus. Liver Int 29, 113-119.
36. Machado M, Marques-Vidal P & Cortez-Pinto H (2006) Hepatic histology in obese patients undergoing bariatric surgery. J Hepatol 45, 600-606.
37. Wagenknecht LE, Scherzinger AL, Stamm ER, et al. (2009) Correlates and heritability of nonalcoholic fatty liver disease in a minority cohort. Obesity 17, 1240-1246.
38. Schwimmer JB, Deutsch R, Kahen T, et al. (2006) Prevalence of fatty liver in children and adolescents. Pediatrics 118, 1388-1393.
39. Adams LA, Lymp JF, Sauver J, et al. (2005) The natural history of nonalcoholic fatty liver disease: A population-based cohort study. Gastroenterology 129, 113-121.
40. Völzke H, Robinson DM, Kleine V, et al. (2005) Hepatic steatosis is associated with an increased risk of carotid atherosclerosis. World J Gastroenterol 11, 1848-1853.
41. Sattar N (2014) Non-Alcoholic fatty liver disease. BMJ 349, g4596.
42. Imamura Y, Uto H, Hiramine Y, et al. (2014) Increasing prevalence of diabetes mellitus in association with fatty liver in a Japanese population. J Gastroenterol 49, 1406-1413.
43. Shibata M, Kihara Y, Taguchi M, et al. (2007) Nonalcoholic fatty liver disease is a risk factor for type 2 diabetes in middle-Aged Japanese men. Diabetes Care 30, 2940-2944.
44. Zhang Y, Zhang T, Zhang C, et al. (2015) Identification of reciprocal causality between non-Alcoholic fatty liver disease and metabolic syndrome by a simplified Bayesian network in a Chinese population. BMJ 5, e008204.
45. De Mutsert R, Den Heijer M, Rabelink TJ, et al. (2013) The Netherlands Epidemiology of Obesity (NEO) study: study design and data collection. Eur J Epidemiol 28, 513-523.
46. Sumida Y, Nakajima A & Itoh Y (2014) Limitations of liver biopsy and non-invasive diagnostic tests for the diagnosis of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. World J Gastroenterol 20, 475-485.
47. Guiu B, Crevisy-Girod E, Binquet C, et al. (2012) Prediction for steatosis in type-2 diabetes: clinico-biological markers versus 1H-MR spectroscopy. Eur Radiol 22, 855-863.
48. Wieckowska A & Feldstein AE (2008) Diagnosis of nonalcoholic fatty liver disease: invasive versus noninvasive. Semin Liver Dis 28, 386-395.
49. Machado MV & Cortez-Pinto H (2013) Non-invasive diagnosis of non-Alcoholic fatty liver disease. A critical appraisal. J Hepatol 58, 1007-1019.
50. Kim H, Taksali SE, Dufour S, et al. (2008) Comparative MR study of hepatic fat quantification using single-voxel proton spectroscopy, two-point Dixon and three-point IDEAL. Magn Reson Med 59, 521-527.
51. Sijens PE, Edens MA, Bakker SJL, et al. (2010) MRI-determined fat content of human liver, pancreas and kidney. World J Gastroenterol 16, 1993-1998.
52. Haus JM, Solomon TPJ, Kelly KR, et al. (2013) Improved hepatic lipid composition following short-Term exercise in nonalcoholic fatty liver disease. J Clin Endocrinol Metab 98, E1181-E1188.
53. Lindeboom L, de Graaf RA, Nabuurs CI, et al. (2016) Quantum coherence spectroscopy to measure dietary fat retention in the liver. JCI Insight 1, e84671.
54. Iozzo P, Lautamaki R, Geisler F, et al. (2004) Non-esterified fatty acids impair insulin-mediated glucose uptake and disposition in the liver. Diabetologia 47, 1149-1156.
55. Labbe SM, Grenier-Larouche T, Noll C, et al. (2012) Increased myocardial uptake of dietary fatty acids linked to cardiac dysfunction in glucose-intolerant humans. Diabetes 61, 2701-2710.
56. Gastaldelli A, Cusi K, Pettiti M, et al. (2007) Relationship between hepatic/visceral fat and hepatic insulin resistance in nondiabetic and type 2 diabetic subjects. Gastroenterology 133, 496-506.
57. Korenblat KM, Fabbrini E, Mohammed BS, et al. (2008) Liver, muscle, and adipose tissue insulin action is directly related to intrahepatic triglyceride content in obese subjects. Gastroenterology 134, 1369-1375.
58. Kotronen A, Juurinen L, Tiikkainen M, et al. (2008) Increased liver fat, impaired insulin clearance, and hepatic and adipose tissue insulin resistance in type 2 diabetes. Gastroenterology 135, 122-130.
59. Kotronen A, Vehkavaara S, Seppälä-Lindroos A, et al. (2007) Effect of liver fat on insulin clearance. Am J Physiol Endocrinol Metab 293, E1709-E1715.
60. Heianza Y, Arase Y, Tsuji H, et al. (2014) Metabolically healthy obesity, presence or absence of fatty liver, and risk of type 2 diabetes in Japanese individuals: Toranomon Hospital Health Management Center Study 20 (TOPICS 20). J Clin Endocrinol Metab 99, 2952-2960.
61. Lorenzo C, Wagenknecht LE, Rewers MJ, et al. (2010) Disposition index, glucose effectiveness, and conversion to type 2 diabetes: The Insulin Resistance Atherosclerosis Study (IRAS). Diabetes Care 33, 2098-2103.
62. Iozzo P, Bucci M, Roivainen A, et al. (2010) Fatty acid metabolism in the liver, measured by positron emission tomography, is increased in obese individuals. Gastroenterology 139, 846-856.
63. Jin ES, Szuszkiewicz-Garcia M, Browning JD, et al. (2015) Influence of liver triglycerides on suppression of glucose production by insulin in men. J Clin Endocrinol Metab 100, 235-243.
64. Amaro A, Fabbrini E, Kars M, et al. (2010) Dissociation between intrahepatic triglyceride content and insulin resistance in familial hypobetalipoproteinemia. Gastroenterology 139, 149-153.
65. Cuthbertson DJ, Shojaee-Moradie F, Sprung VS, et al. (2016) Dissociation between exercise-induced reduction in liver fat and changes in hepatic and peripheral glucose homoeostasis in obese patients with non-Alcoholic fatty liver disease. Clin Sci 130, 93-104.
66. Sanyal AJ, Campbell-Sargent C, Mirshahi F, et al. (2001) Nonalcoholic steatohepatitis: Association of insulin resistance and mitochondrial abnormalities. Gastroenterology 120, 1183-1192.
67. Gentile CL, Frye MA & Pagliassotti MJ (2011) Fatty acids and the endoplasmic reticulum in nonalcoholic fatty liver disease. BioFactors 37, 8-16.
68. Xu X, So JS, Park JG, et al. (2013) Transcriptional control of hepatic lipid metabolism by SREBP and ChREBP. Semin Liver Dis 33, 301-311.
69. Valtuena S, Pellegrini N, Ardigó D, et al. (2006) Dietary glycemic index and liver steatosis. Am J Clin Nutr 84, 136-142.
70. Keyhani-Nejad F, Irmler M, Isken F, et al. (2014) Nutritional strategy to prevent fatty liver and insulin resistance independent of obesity by reducing glucose-dependent insulinotropic polypeptide responses in mice. Diabetologia 58, 374-383.
71. Tang A, Rabasa-Lhoret R, Castel H, et al. (2015) Effects of insulin glargine and liraglutide therapy on liver fat as measured by magnetic resonance in patients with type 2 diabetes: A randomized trial. Diabetes Care 38, 1339-1346.
72. Rudovich NN, Weickert MO, Machann J, et al. (2010) Combination of acarbose and ezetimibe prevents non-Alcoholic fatty liver disease: A break of intestinal insulin resistance? J Hepatol 52, 952-953.
73. Isken F, Klaus S, Petzke KJ, et al. (2010) Impairment of fat oxidation under high- vs. low-glycemic index diet occurs before the development of an obese phenotype. Am J Physiol Endocrinol Metab 298, E287-E295.
74. Browning JD, Baker JA, Rogers T, et al. (2011) Short-Term weight loss and hepatic triglyceride reduction: Evidence of a metabolic advantage with dietary carbohydrate restriction. Am J Clin Nutr 93, 1048-1052.
75. Kruse M, von Loeffelholz C, Hoffmann D, et al. (2015) Dietary rapeseed/canola-oil supplementation reduces serum lipids and liver enzymes and alters postprandial inflammatory responses in adipose tissue compared to olive-oil supplementation in obese men. Mol Nutr Food Res 59, 507-519.
76. Nowotny B, Zahiragic L, Bierwagen A, et al. (2014) Low-energy diets differing in fibre, red meat and coffee intake equally improve insulin sensitivity in type 2 diabetes: A randomised feasibility trial. Diabetologia 58, 255-264.
77. Byrne CD & Targher G (2015) NAFLD: A multisystem disease. J Hepatol 62, S47-S64.
78. Sung K-C, Jeong W-S, Wild SH, et al. (2012) Combined influence of insulin resistance, overweight/obesity, and fatty liver as risk factors for type 2 diabetes. Diabetes Care 35, 717-722.
79. Sung K-C, Wild SH & Byrne CD(2013) Resolution of fatty liver and risk of incident diabetes. J Clin Endocrinol Metab 98, 3637-3643.
80. Oni ET, Agatston AS, Blaha MJ, et al. (2013) A systematic review: burden and severity of subclinical cardiovascular disease among those with nonalcoholic fatty liver; should we care? Atherosclerosis 230, 258-267.
81. Stepanova M & Younossi ZM (2012) Independent association between nonalcoholic fatty liver disease and cardiovascular disease in the US population. Clin Gastroenterol Hepatol 10, 646-650.
82. Targher G, Bertolini L, Padovani R, et al. (2007) Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. Diabetes Care 30, 1212-1218.
83. Bhatia LS, Curzen NP, Calder PC, et al. (2012) Non-Alcoholic fatty liver disease: A new and important cardiovascular risk factor? Eur Heart J 33, 1190-1200.
84. Mantovani A, Pernigo M, Bergamini C, et al. (2015) Heart valve calcification in patients with type 2 diabetes and nonalcoholic fatty liver disease. Metabolism 64, 879-887.
85. Targher G, Valbusa F, Bonapace S, et al. (2013) Non-Alcoholic fatty liver disease is associated with an increased incidence of atrial fibrillation in patients with type 2 diabetes. PLOS ONE 8, e57183.
86. Sung K-C, Wild SH & Byrne CD (2014) Development of new fatty liver, or resolution of existing fatty liver, over five years of follow-up, and risk of incident hypertension. J Hepatol 60, 1040-1045.
87. Nobili V, Alisi A, Musso G, et al. (2016) Omega-3 fatty acids: mechanisms of benefit and therapeutic effects in pediatric and adult NAFLD. Crit Rev Clin Lab Sci 53, 106-120.
88. Sanyal AJ, Abdelmalek MF, Suzuki A, et al. (2014) No significant effects of ethyl-eicosapentanoic acid on histologic features of nonalcoholic steatohepatitis in a phase 2 trial. Gastroenterology 147, 377-384.
89. Scorletti E, Bhatia L, McCormick KG, et al. (2014) Effects of purified eicosapentaenoic and docosahexaenoic acids in nonalcoholic fatty liver disease: Results from the WELCOME study. Hepatology 60, 1211-1221.
90. Dongiovanni P & Valenti L (2016) Genetics of nonalcoholic fatty liver disease. Metabolism 65, 1026-1037.
91. Nobili V, Bedogni G, Donati B, et al. (2013) The I148M variant of PNPLA3 reduces the response to docosahexaenoic acid in children with non-Alcoholic fatty liver disease. J Med Food 16, 957-960.
92. Scorletti E, West AL, Bhatia L, et al. (2015) Treating liver fat and serum triglyceride levels in NAFLD, effects of PNPLA3 and TM6SF2 genotypes: Results from the WELCOME trial. J Hepatol 63, 1476-1483.
93. Banerjee R, Pavlides M, Tunnicliffe EM, et al. (2014)Multiparametric magnetic resonance for the non-invasive diagnosis of liver disease. J Hepatol 60, 69-77.
94. Pavlides M, Banerjee R, Sellwood J, et al. (2016) Multiparametric magnetic resonance imaging predicts clinical outcomes in patients with chronic liver disease. J Hepatol 64, 308-315.
95. Byrne CD & Targher G (2016) Time to replace assessment of liver histology with MR-based imaging tests to assess efficacy of interventions for nonalcoholic fatty liver disease. Gastroenterology 150, 7-10.
96. Sato F, Tamura Y, Watada H, et al. (2007) Brief report: Effects of diet-induced moderate weight reduction on intrahepatic and intramyocellular triglycerides and glucose metabolism in obese subjects. J Clin Endocrinol Metab 92, 3326-3329.
97. Viljanen APM, Iozzo P, Borra R, et al. (2009) Effect of weight loss on liver free fatty acid uptake and hepatic insulin resistance. J Clin Endocrinol Metab 94, 50-55.
98. Bortolotti M, Kreis R, Debard C, et al. (2009) High protein intake reduces intrahepatocellular lipid deposition in humans. Am J Clin Nutr 90, 1002-1010.
99. Van Der Meer RW, Hammer S, Lamb HJ, et al. (2008) Effects of short-Term high-fat, high-energy diet on hepatic and myocardial triglyceride content in healthy men. J Clin Endocrinol Metab 93, 2702-2708.
100. Kirk E, Reeds DN, Finck BN, et al. (2009) Dietary fat and carbohydrates differentially alter insulin sensitivity during caloric restriction. Gastroenterology 136, 1552-1560.
101. Ryan MC, Abbasi F, Lamendola C, et al. (2007) Serum alanine aminotransferase levels decrease further with carbohydrate than fat restriction in insulin-resistant adults. Diabetes Care 30, 1075-1080.
102. Westerbacka J, Lammi K, Haekkinen A-M, et al. (2005) Dietary fat content modifies liver fat in overweight nondiabetic subjects. J Clin Endocrinol Metab 90, 2804-2809.
103. Allard JP, Aghdassi E, Mohammed S, et al. (2008)Nutritional assessment and hepatic fatty acid composition in non-Alcoholic fatty liver disease (NAFLD): A cross-sectional study. J Hepatol 48, 300-307.
104. Musso G, Gambino R, De Michieli F, et al. (2003) Dietary habits and their relations to insulin resistance and postprandial lipemia in nonalcoholic steatohepatitis. Hepatology 37, 909-916.
105. PeterssonH, Arnlöv J, Zethelius B, et al. (2010) Serumfatty acid composition and insulin resistance are independently associated with liver fat markers in elderly men. Diabetes Res Clin Pract 87, 379-384.
106. Petit JM, Guiu B, Duvillard L, et al. (2012) Increased erythrocytes n-3 and n-6 polyunsaturated fatty acids is significantly associated with a lower prevalence of steatosis in patients with type 2 diabetes. Clin Nutr 31, 520-525.
107. Risérus U, Willett WC & Hu FB (2009) Dietary fats and prevention of type 2 diabetes. Prog Lipid Res 48, 44-51.
108. De Wit NJW, Afman LA, Mensink M, et al. (2012) Phenotyping the effect of diet on non-Alcoholic fatty liver disease. J Hepatol 57, 1370-1373.
109. DeLany JP, Windhauser MM, Champagne CM, et al. (2000) Differential oxidation of individual dietary fatty acids in humans. Am J Clin Nutr 72, 905-911.
110. Parker HM, Johnson NA, Burdon CA, et al. (2012) Omega-3 supplementation and non-Alcoholic fatty liver disease: A systematic review and meta-Analysis. J Hepatol 56, 944-951.
111. Argo CK, Patrie JT, Lackner C, et al. (2015) Effects of n-3 fish oil on metabolic and histological parameters in NASH: A doubleblind, randomized, placebo-controlled trial. J Hepatol 62, 190-197.
112. Delarue J & Lallès J-P (2016) Nonalcoholic fatty liver disease: Roles of the gut and the liver and metabolic modulation by some dietary factors and especially long-chain n-3 PUFA. Mol Nutr Food Res 60, 147-159.
113. Sevastianova K, Santos A, Kotronen A, et al. (2012) Effect of short-Term carbohydrate overfeeding and long-Term weight loss on liver fat in overweight humans. Am J Clin Nutr 96, 727-734.
114. Lecoultre V, Egli L, Carrel G, et al. (2013) Effects of fructose and glucose overfeeding on hepatic insulin sensitivity and intrahepatic lipids in healthy humans. Obesity 21, 782-785.
115. Maersk M, Belza A, Stoedkilde-Joergensen H, et al. (2012) Sucrose-sweetened beverages increase fat storage in the liver, muscle, and visceral fat depot: A 6-mo randomized intervention study. Am J Clin Nutr 95, 283-289.
116. Pastori D, Baratta F, Carnevale R, et al. (2015) Similar reduction of cholesterol-Adjusted vitamin E serum levels in simple steatosis and non-Alcoholic steatohepatitis. Clin Trans Gastroenterol 6, e113.
117. Watanabe S, Hashimoto E, Ikejima K, et al. (2015) Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. J Gastroenterol 50, 364-377.
118. Kwok RM, Torres DM & Harrison SA (2013) Vitamin D and nonalcoholic fatty liver disease (NAFLD): is it more than just an association? Hepatology 58, 1166-1174.
119. Chachay VS, Macdonald GA, Martin JH, et al. (2014) Resveratrol does not benefit patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 12, 2092-2103.
120. Yki-Järvinen H (2010) Nutritional modulation of nonalcoholic fatty liver disease and insulin resistance: human data. Curr Opin Clin Nutr Metab Care 13, 709-714.